Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Schölkens BA[au]:

Kinins in the cardiovascular system. Schölkens BA et al. Immunopharmacology. (1996)

Kinins and cardioprotection. Wirth KJ et al. Pharmacol Res. (1997)

Beneficial effects of bradykinin on myocardial energy metabolism and infarct size. Linz W et al. Am J Cardiol. (1997)

Search results

Items: 1 to 50 of 139

1.

ACE inhibition and atherogenesis.

Schölkens BA, Landgraf W.

Can J Physiol Pharmacol. 2002 Apr;80(4):354-9. Review.

PMID:
12025972
2.

Tissue kallikrein KLK1 is expressed de novo in endothelial cells and mediates relaxation of human umbilical veins.

Dedio J, Wiemer G, Rütten H, Dendorfer A, Schölkens BA, Müller-Esterl W, Wohlfart P.

Biol Chem. 2001 Oct;382(10):1483-90.

PMID:
11727832
3.

[ACE inhibition and atherogenesis].

Schölkens BA, Landgraf W.

Internist (Berl). 2001 Sep;42(9):1219-25. Review. German. No abstract available.

PMID:
11571850
4.

Long-term angiotensin II type 1 receptor blockade with fonsartan doubles lifespan of hypertensive rats.

Linz W, Heitsch H, Schölkens BA, Wiemer G.

Hypertension. 2000 Apr;35(4):908-13.

PMID:
10775560
5.

The K(ATP) channel blocker HMR 1883 does not abolish the benefit of ischemic preconditioning on myocardial infarct mass in anesthetized rabbits.

Jung O, Englert HC, Jung W, Gögelein H, Schölkens BA, Busch AE, Linz W.

Naunyn Schmiedebergs Arch Pharmacol. 2000 Apr;361(4):445-51.

PMID:
10763861
6.

Interactions among ACE, kinins and NO.

Linz W, Wohlfart P, Schölkens BA, Malinski T, Wiemer G.

Cardiovasc Res. 1999 Aug 15;43(3):549-61. Review. No abstract available.

PMID:
10690327
7.

K(ATP) channel blocker HMR 1883 reduces monophasic action potential shortening during coronary ischemia in anesthetised pigs.

Wirth KJ, Uhde J, Rosenstein B, Englert HC, Gögelein H, Schölkens BA, Busch AE.

Naunyn Schmiedebergs Arch Pharmacol. 2000 Feb;361(2):155-60.

PMID:
10685870
8.

HMR 1883, a cardioselective K(ATP) channel blocker, inhibits ischaemia- and reperfusion-induced ventricular fibrillation in rats.

Wirth KJ, Klaus E, Englert HG, Schölkens BA, Linz W.

Naunyn Schmiedebergs Arch Pharmacol. 1999 Sep;360(3):295-300.

PMID:
10543431
9.

ATP-sensitive potassium channel blocker HMR 1883 reduces mortality and ischemia-associated electrocardiographic changes in pigs with coronary occlusion.

Wirth KJ, Rosenstein B, Uhde J, Englert HC, Busch AE, Schölkens BA.

J Pharmacol Exp Ther. 1999 Nov;291(2):474-81.

PMID:
10525061
10.

Effect of long-term ACE inhibition on myocardial tissue in hypertensive stroke-prone rats.

Zimmermann R, Kastens J, Linz W, Wiemer G, Schölkens BA, Schaper J.

J Mol Cell Cardiol. 1999 Aug;31(8):1447-56.

PMID:
10423343
11.

Variable renal atrial natriuretic factor gene expression in hypertension.

Ogawa T, Linz W, Schölkens BA, de Bold AJ.

Hypertension. 1999 Jun;33(6):1342-7.

PMID:
10373213
12.

Novel series of O-substituted 8-quinolines and 4-benzothiazoles as potent antagonists of the bradykinin B2 receptors.

Heitsch H, Wagner A, Schölkens BA, Wirth K.

Bioorg Med Chem Lett. 1999 Feb 8;9(3):327-32.

PMID:
10091678
13.

Regulation of aortic atrial natriuretic factor and angiotensinogen in experimental hypertension.

Ogawa T, Linz W, Schölkens BA, de Bold AJ.

J Cardiovasc Pharmacol. 1998 Dec;32(6):1001-8.

PMID:
9869508
14.

Nephroprotection by long-term ACE inhibition with ramipril in spontaneously hypertensive stroke prone rats.

Linz W, Becker RH, Schölkens BA, Wiemer G, Keil M, Langer KH.

Kidney Int. 1998 Dec;54(6):2037-44.

15.

Dose-dependent reduction of myocardial infarct mass in rabbits by the NHE-1 inhibitor cariporide (HOE 642).

Linz W, Albus U, Crause P, Jung W, Weichert A, Schölkens BA, Scholz W.

Clin Exp Hypertens. 1998 Oct;20(7):733-49.

PMID:
9764718
17.
18.

Intracellular pH regulation in bovine aortic endothelial cells: evidence of both Na+/H+ exchange and Na+-dependent Cl-/HCO3- exchange.

Faber S, Lang HJ, Hock FJ, Schölkens BA, Mutschler E.

Cell Physiol Biochem. 1998;8(4):202-11.

PMID:
9694347
19.

Bradykinin antagonists with dehydrophenylalanine analogues at position 5.

Greiner G, Dornberger U, Paegelow I, Schölkens BA, Liebmann C, Reissmann S.

J Pept Sci. 1998 Apr;4(2):92-100.

PMID:
9620613
20.

Anaphylactoid reactions during hemodialysis in sheep are ACE inhibitor dose-dependent and mediated by bradykinin.

Krieter DH, Grude M, Lemke HD, Fink E, Bönner G, Schölkens BA, Schulz E, Müller GA.

Kidney Int. 1998 Apr;53(4):1026-35.

21.

Long-term ACE inhibition doubles lifespan of hypertensive rats.

Linz W, Jessen T, Becker RH, Schölkens BA, Wiemer G.

Circulation. 1997 Nov 4;96(9):3164-72.

PMID:
9386189
22.

The bradykinin B2 receptor antagonist Icatibant (HOE 140) corrects avid Na+ retention in rats with CCl4-induced liver cirrhosis: possible role of enhanced microvascular leakage.

Wirth KJ, Bickel M, Hropot M, Günzler V, Heitsch H, Ruppert D, Schölkens BA.

Eur J Pharmacol. 1997 Oct 15;337(1):45-53.

PMID:
9389380
23.

Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats.

Wiemer G, Linz W, Hatrik S, Schölkens BA, Malinski T.

Hypertension. 1997 Nov;30(5):1183-90.

PMID:
9369274
24.

Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production.

Bouloumié A, Bauersachs J, Linz W, Schölkens BA, Wiemer G, Fleming I, Busse R.

Hypertension. 1997 Oct;30(4):934-41.

PMID:
9336396
25.

Beneficial effects of bradykinin on myocardial energy metabolism and infarct size.

Linz W, Wiemer G, Schölkens BA.

Am J Cardiol. 1997 Aug 4;80(3A):118A-123A. Review.

PMID:
9293964
26.

Early induction of angiotensin I-converting enzyme in rat carotid artery after balloon injury.

Fernandez-Alfonso MS, Martorana PA, Licka I, van Even P, Trobisch D, Schölkens BA, Paul M.

Hypertension. 1997 Aug;30(2 Pt 1):272-7.

PMID:
9260992
27.

Kinins and cardioprotection.

Wirth KJ, Linz W, Wiemer G, Schölkens BA.

Pharmacol Res. 1997 Jun;35(6):527-30. Review.

PMID:
9356203
28.

Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression.

Nickenig G, Jung O, Strehlow K, Zolk O, Linz W, Schölkens BA, Böhm M.

Am J Physiol. 1997 Jun;272(6 Pt 2):H2701-7.

PMID:
9227549
29.

Different B1 kinin receptor expression and pharmacology in endothelial cells of different origins and species.

Wohlfart P, Dedio J, Wirth K, Schölkens BA, Wiemer G.

J Pharmacol Exp Ther. 1997 Feb;280(2):1109-16.

PMID:
9023330
30.

Effects of the Na+/H+-exchange inhibitor Hoe 642 on intracellular pH, calcium and sodium in isolated rat ventricular myocytes.

Russ U, Balser C, Scholz W, Albus U, Lang HJ, Weichert A, Schölkens BA, Gögelein H.

Pflugers Arch. 1996 Nov-Dec;433(1-2):26-34.

PMID:
9019727
31.

Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats.

Gohlke P, Linz W, Schölkens BA, Wiemer G, Unger T.

Hypertension. 1996 Sep;28(3):397-402.

PMID:
8794823
32.

ACE inhibition decreases postoperative mortality in rats with left ventricular hypertrophy and myocardial infarction.

Linz W, Wiemer G, Schmidts HL, Ulmer W, Ruppert D, Schölkens BA.

Clin Exp Hypertens. 1996 Jul;18(5):691-712.

PMID:
8781754
33.

Efficacy and tolerability of Icatibant (Hoe 140) in patients with moderately severe chronic bronchial asthma.

Akbary AM, Wirth KJ, Schölkens BA.

Immunopharmacology. 1996 Jun;33(1-3):238-42.

PMID:
8856156
34.

Kinins in the cardiovascular system.

Schölkens BA.

Immunopharmacology. 1996 Jun;33(1-3):209-16. Review.

PMID:
8856152
35.

Differences in acetylcholine- and bradykinin-induced vasorelaxation of the mesenteric vascular bed in spontaneously hypertensive rats of different ages.

Wirth KJ, Linz W, Wiemer G, Schölkens BA.

Naunyn Schmiedebergs Arch Pharmacol. 1996 Jun;354(1):38-43.

PMID:
8832586
36.

Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production.

Ogawa T, Linz W, Stevenson M, Bruneau BG, Kuroski de Bold ML, Chen JH, Eid H, Schölkens BA, de Bold AJ.

Circulation. 1996 Jun 1;93(11):2059-67.

PMID:
8640983
37.
38.

Role of kinins in myocardial ischemia.

Linz W, Martorana PA, Wiemer G, Wirth K, Schölkens BA.

EXS. 1996;76:231-41. Review. No abstract available.

PMID:
8805798
39.

Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies.

Linz W, Wiemer G, Schölkens BA.

Diabetes. 1996 Jan;45 Suppl 1:S51-8. Review.

PMID:
8529801
40.

Technetium-99m-labeled HOE 140: a potential bradykinin B2 receptor imaging agent.

Stahl W, Breipohl G, Kuhlmann L, Steinsträsser A, Gerhards HJ, Schölkens BA.

J Med Chem. 1995 Jul 21;38(15):2799-801. No abstract available.

PMID:
7636840
41.

Kinin receptor antagonists: unique probes in basic and clinical research.

Wirth KJ, Heitsch H, Schölkens BA.

Can J Physiol Pharmacol. 1995 Jul;73(7):797-804. Review.

PMID:
8846412
42.

Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis.

Linz W, Wiemer G, Schaper J, Zimmermann R, Nagasawa K, Gohlke P, Unger T, Schölkens BA.

Mol Cell Biochem. 1995 Jun 7-21;147(1-2):89-97. Review.

PMID:
7494560
43.

Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.

Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA.

Pharmacol Rev. 1995 Mar;47(1):25-49. Review.

PMID:
7784479
44.

Protective effects of HOE642, a selective sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfusion.

Scholz W, Albus U, Counillon L, Gögelein H, Lang HJ, Linz W, Weichert A, Schölkens BA.

Cardiovasc Res. 1995 Feb;29(2):260-8.

PMID:
7736504
45.

Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction.

Linz W, Gohlke P, Unger T, Schölkens BA.

Arch Mal Coeur Vaiss. 1995 Feb;88 Spec No 2:31-4.

PMID:
7646309
46.

The bradykinin B2 receptor antagonist WIN 64338 inhibits the effect of des-Arg9-bradykinin in endothelial cells.

Wirth KJ, Schölkens BA, Wiemer G.

Eur J Pharmacol. 1994 Dec 15;288(1):R1-2.

PMID:
7705460
47.

Ramipril prevents the detrimental sequels of chronic NO synthase inhibition in rats: hypertension, cardiac hypertrophy and renal insufficiency.

Hropot M, Grötsch H, Klaus E, Langer KH, Linz W, Wiemer G, Schölkens BA.

Naunyn Schmiedebergs Arch Pharmacol. 1994 Dec;350(6):646-52.

PMID:
7535899
48.

Cardioprotective actions of bradykinin in myocardial ischemia and left ventricular hypertrophy.

Linz W, Wiemer G, Schölkens BA.

Braz J Med Biol Res. 1994 Aug;27(8):1949-54.

PMID:
7749386
49.

Effects of the renin inhibitor N-[N-(3-(4-amino-1-piperidinyl-carbonyl)-2(R)-benzylpropionyl)-L- histid inyl] -(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6(2-pyridyl)-hexane-2-amide acetate in anesthetized rhesus monkeys.

Linz W, Heitsch H, Henning R, Jung W, Kleemann HW, Nickel WU, Ruppert D, Urbach H, Wagner A, Schölkens BA.

Arzneimittelforschung. 1994 Jul;44(7):815-20.

PMID:
7945514
50.

Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin.

Gohlke P, Linz W, Schölkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T.

Hypertension. 1994 Apr;23(4):411-8.

PMID:
8144208

Supplemental Content

Loading ...
Support Center